V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310009708 | 310005058 | 1.65 | 70 | Palliative (P) | 2017-03-05 | 2017-03-10 | Eribulin | N | N | 310019901 | SUNITINIB |
| 310009711 | 310008208 | 1.72 | 83.3 | Palliative (P) | 2013-08-25 | 2013-12-02 | METHOTREXATE + PEGASPARGASE | N | null | 310019928 | R-EPOCH |
| 310009712 | 310005064 | 1.5 | 59.7 | Curative (C) | 2018-10-11 | 2018-10-11 | BCG Intravesical | 02 | N | 310019932 | CTD |
| 310009713 | 310005065 | 1.59 | 65.8 | Curative (C) | null | 2018-07-05 | LANREOTIDE | N | null | 310019932 | PAZOPANIB |
| 310009714 | 310008211 | 1.69 | 72.5 | Palliative (P) | 2015-04-13 | 2015-04-14 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | null | 310019947 | CARBOPLATIN + PEMETREXED |
| 310009715 | 310008212 | 1.82 | null | Palliative (P) | 2014-01-24 | 2015-10-16 | Bortezomib +/- Dexamethasone | Y | N | 310019955 | R-EPOCH |
| 310009716 | 310009872 | 1.62 | 79.6 | Curative (C) | 2016-08-05 | 2016-08-05 | Cyclophosphamide Fludarabine (Oral) | N | N | 310019956 | PMITCEBO |
| 310009717 | 310011287 | 1.65 | 72 | Palliative (P) | 2016-07-13 | 2016-08-04 | Retinoblastoma JOE | Y | N | 310019959 | DABRAFENIB + TRAMETINIB |
| 310009718 | 310008213 | 1.54 | 65 | Palliative (P) | 2016-12-12 | 2016-12-12 | Trabectedin | N | N | 310019962 | CISPLATIN + ETOPOSIDE |
| 310009719 | 310005075 | 1.96 | 66.9 | null | 2016-10-08 | 2016-11-08 | DABRAFENIB + TRAMETINIB | N | N | 310019971 | BENDAMUSTINE |
| 310009720 | 310009875 | 1.73 | 67.3 | Curative (C) | 2013-07-10 | 2013-07-19 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 310019978 | RUXOLITINIB |
| 310009721 | 310005078 | 1.78 | null | Palliative (P) | 2014-08-19 | 2014-08-29 | Chlorambucil | N | N | 310019979 | CYTARABINE HD + METHOTREXATE HD |
| 310009722 | 310005081 | 1.65 | 69 | Adjuvant (A) | 2019-01-15 | 2019-01-15 | Temozolomide 200mg/m2 | null | N | 310019991 | OLAPARIB |
| 310009723 | 310008220 | 1.57 | null | Palliative (P) | 2014-12-19 | 2015-06-12 | METHOTREXATE | 02 | null | 310019995 | AZACITIDINE |
| 310009724 | 310008221 | null | 79.4 | Curative (C) | 2017-07-07 | 2017-11-03 | Carboplatin + Docetaxel | N | null | 310019998 | SUNITINIB |
| 310009725 | 310005086 | 1.77 | 67.9 | Curative (C) | 2018-01-01 | 2018-04-29 | BEAM + FLUDARABINE | N | null | 310020002 | ALEMTUZUMAB |
| 310009726 | 310005087 | 1.62 | 75 | Curative (C) | 2016-01-17 | 2015-09-28 | Atezolizumab | N | N | 310020003 | OXALIPLATIN + MDG |
| 310009727 | 310005087 | 1.68 | 56.4 | Curative (C) | 2014-11-14 | 2015-03-14 | PMitCEBO | N | N | 310020003 | EMA |
| 310009728 | 310011931 | 1.65 | 70.6 | Palliative (P) | 2013-11-19 | 2013-11-26 | BENDAMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 2 | N | 310020015 | DOXORUBICIN |
| 310009729 | 310011931 | 1.67 | 74.4 | Palliative (P) | 2017-03-01 | 2017-03-03 | BEVACIZUMAB + CARBO | N | N | 310020015 | PENTOSTATIN |
| 310009730 | 310008224 | 1.66 | null | Palliative (P) | 2015-10-17 | 2015-10-17 | CETUXIMAB + RT | 02 | N | 310020025 | DABRAFENIB |
| 310009731 | 310005092 | null | 56 | Curative (C) | 2015-11-30 | 2015-12-06 | FLUOROURACIL + MITOMYCIN | null | null | 310020055 | METHOTREXATE |
| 310009732 | 310005093 | 1.33 | 58 | Palliative (P) | 2014-06-24 | 2014-06-24 | LENALIDOMIDE | 02 | N | 310020060 | CAPECITABINE + CISPLATIN |
| 310009733 | 310005096 | 1.95 | 66 | Disease modification (D) | 2017-02-18 | 2018-05-13 | METHOTREXATE | N | N | 310020064 | LACE |
| 310009734 | 310005098 | 0 | 77 | Curative (C) | 2017-08-07 | 2017-08-22 | Cytarabine HD + Methotrexate HD | N | N | 310020066 | PEG INTERFERON |
| 310009735 | 310005100 | 1.84 | 92.7 | Curative (C) | 2016-06-15 | 2016-06-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 310020071 | TRIPLE INTRATHECAL |
| 310009736 | 310005101 | 1.59 | 0 | Curative (C) | 2016-07-28 | 2016-08-14 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 310020075 | BENDAMUSTINE |
| 310009737 | 310005103 | null | 63.9 | Curative (C) | 2017-09-20 | 2018-04-04 | CHLVPP | 2 | N | 310020087 | TOPOTECAN |
| 310009738 | 310005105 | null | 59.7 | c | 2014-05-31 | 2014-07-08 | Capecitabine | 02 | N | 310020094 | RMS 2005 TRIAL |
| 310009739 | 310011740 | 1.55 | null | Curative (C) | null | 2013-05-24 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 310020104 | CYTARABINE INTRATHECAL |
| 310009740 | 310005107 | null | 70.1 | Curative (C) | 2017-02-22 | 2017-04-14 | Topotecan IV 7 day | N | N | 310020108 | TEMOZOLOMIDE |
| 310009741 | 310005108 | 1.78 | 61 | Curative (C) | 2015-09-20 | 2015-09-20 | PEG INTERFERON | N | N | 310020113 | INTERFERON |
| 310009742 | 310011741 | 0 | 59.7 | Palliative (P) | 2015-07-14 | 2015-07-17 | CVD | N | N | 310020119 | ATEZOLIZUMAB |
| 310009743 | 310011897 | 1.62 | 0 | Curative (C) | 2015-12-08 | 2016-03-07 | Hydroxycarbamide | N | N | 310020123 | MITOMYCIN |
| 310009744 | 310008237 | 1.46 | null | Adjuvant (A) | 2016-10-27 | 2016-12-30 | EOX | N | null | 310020124 | DOXORUBICIN + IFOSFAMIDE |
| 310009745 | 310005115 | 1.67 | 82 | Disease modification (D) | 2016-06-14 | 2016-06-25 | DABRAFENIB | N | N | 310020155 | ALEMTUZUMAB |
| 310009746 | 310005117 | 1.77 | 140 | Palliative (P) | 2015-01-12 | 2015-01-12 | Methotrexate High Dose (3g/m2) | 02 | N | 310020163 | CAPECITABINE + OXALIPLATIN |
| 310009747 | 310005121 | 1.71 | 80.7 | Curative (C) | 2015-04-01 | 2015-04-02 | ICE (no GCSF) | N | N | 310020170 | DABRAFENIB + TRAMETINIB |
| 310009749 | 310005127 | 1.62 | 0 | Curative (C) | 2014-05-28 | 2014-06-04 | Alemtuzumab | N | N | 310020176 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 310009750 | 310005129 | 1.8 | 118 | Curative (C) | 2016-09-03 | 2017-02-15 | ATG + Busulfan + Fludarabine + Thiotepa | 2 | N | 310020177 | VIDE |
| 310009751 | 310011292 | 1.74 | 96.5 | Disease modification (D) | 2014-04-11 | 2014-04-18 | CARBOPLATIN + RT | 02 | null | 310020179 | EOX |
| 310009752 | 310005131 | 0 | 56 | Curative (C) | 2014-08-20 | 2014-09-25 | Atezolizumab | null | N | 310020187 | MCX |
| 310009753 | 310005133 | 1.66 | 68.4 | Curative (C) | 2016-09-02 | 2016-09-13 | Methotrexate High Dose (3g/m2) | 2 | N | 310020191 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 310009754 | 310005134 | 1.84 | 73.6 | Disease modification (D) | 2016-08-22 | 2016-08-22 | Gemcitabine + Oxaliplatin | N | N | 310020192 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 310009755 | 310005134 | 1.84 | 66.7 | Palliative (P) | 2015-10-26 | 2016-06-29 | IVE-R | N | null | 310020192 | ALEMTUZUMAB |
| 310009760 | 310008248 | 1.74 | null | Disease modification (D) | null | 2017-07-13 | BEAM + Alemtuzumab Allo SCT | null | null | 310020217 | METHOTREXATE |
| 310009761 | 310011295 | 1.53 | null | Palliative (P) | 2015-01-25 | 2015-01-25 | Capecitabine | N | N | 310020221 | TRASTUZUMAB |
| 310009762 | 310005139 | null | 45.8 | Palliative (P) | 2016-09-13 | 2016-09-18 | Everolimus 10mg | 02 | N | 310020227 | OCTOPUS TRIAL |
| 310009763 | 310010789 | null | null | Palliative (P) | 2016-01-25 | 2016-03-08 | CLADRIBINE | N | N | 310020230 | ICON TRIAL |
| 310009764 | 310005141 | 1.79 | null | null | 2018-07-28 | 2018-09-25 | Trastuzumab Subcutaneous | 02 | N | 310020245 | IVE + METHOTREXATE |